Abstract
Background Antiretroviral therapy (ART) decreases perinatal HIV transmission, but concerns exist regarding maternal and infant safety. We compared the incidence of congenital malformations and other adverse outcomes in pregnancies exposed to integrase inhibitor (INSTI) versus non-INSTI ART.
Setting Single-site review of all pregnancies among women living with HIV between 2008 and 2018. Methods: We used binomial family generalized estimating equations to model the relationship of congenital anomalies and pregnancy outcomes with exposure to INSTI or dolutegravir (DTG) versus non-INSTI ART. Results: Among 257 pregnancies, 77 women received ≥1 INSTI (54 DTG, 14 elvitegravir, 15 raltegravir), 167 received non-INSTI, and 3 had missing data. Forty-nine congenital anomalies were identified among 36 infants. Infants with first-trimester DTG or any first-trimester INSTI exposure had higher odds of congenital anomalies than infants with first-trimester non-INSTI exposure (OR=2.55; 95%CI=1.07-6.10; OR=2.61; 95%CI=1.15-5.94, respectively). Infants with INSTI exposure after the second trimester had no increased odds of anomalies. Women with INSTI exposure had higher odds of preeclampsia (OR=4.73; 95%CI=1.70-13.19). Among women who received INSTI, grade ≥3 laboratory abnormalities were noted in 2.6% while receiving the INSTI and 3.9% while not receiving the INSTI, versus 16.2% in women who received non-INSTI. There was no association between INSTI exposure and other pregnancy outcomes.
Conclusion First-trimester INSTI exposure may be associated with increased rates of congenital anomalies. Use of INSTI during pregnancy was also associated with preeclampsia in our cohort. These findings underscore the need for continued monitoring of the safety of INSTI in pregnancy.
Competing Interest Statement
I have read the journal's policy and the authors of this manuscript have the following competing interests: Adriana Weinberg discloses research grants from GlaxoSmithKline and Merck that were paid to the University of Colorado and personal fees from Merck, Squirus and GlaxoSmithKline for work unrelated to this study. The remaining authors have declared that no competing interests exist.
Funding Statement
Institutional funding supported this study. The CHIP clinic receives funding from award numbers: HHSN275201800001I 5P01HD103133-02 5U01HD068063-05 5U01HD068040474-15S1 UM1 AI068619 ENVHL-202158734-00 X0700056 H12HA24784. Through access to University of Colorado REDCap, this project was supported by NIH/NCATS Colorado CTSA Grant Number UL1 TR002535. Its contents are the authors’ sole responsibility and do not necessarily represent official NIH views. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Colorado Multiple Institutional Review Board (COMIRB) with a waiver of informed consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵^ Membership of the CHIP Perinatal Medical Team is provided in the Acknowledgments.
Data Availability
All relevant data are within the manuscript and its Supporting Information files.